Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
Carcinoma, Non-Small-Cell Lung
Gene Expression Regulation, Neoplastic
Seventy-two patients with advanced prostatic carcinoma without previous endocrine therapy were treated with an oral nonsteroidal antiandrogen, flutamide. Sixty-three patients (87.5%) had a favorable response, and 9 patients showed no response. Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.